Cidara Therapeutics, Inc. (CDTX)

Cidara Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	293.65	189.83	35.78	32.73	59.68	35.91
Short-Term Investments	126.37	-	-	-	-	-
Cash & Short-Term Investments	420.02	189.83	35.78	32.73	59.68	35.91
Cash Growth	229.72%	430.56%	9.31%	-45.16%	66.18%	-28.56%
Accounts Receivable	1.86	1.69	14.08	5.72	5.36	11.18
Receivables	1.86	1.69	14.08	5.72	5.36	11.18
Prepaid Expenses	14.6	12.87	1.71	5.58	4.07	3.07
Restricted Cash	6.34	6.35	-	-	2.59	7.04
Other Current Assets	-	-	9.29	1.07	-	-
Total Current Assets	442.82	210.74	60.86	45.09	71.7	57.19
Property, Plant & Equipment	2.09	3.96	5.13	1.32	2.54	1.21
Other Long-Term Assets	23.58	0.1	1.05	1.07	1.08	2.02
Total Assets	518.65	214.8	67.03	47.49	75.33	60.42

Liabilities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Accounts Payable	4.35	3.61	3.77	1.45	1.3	4.57
Accrued Expenses	89.93	44.3	37.25	24.13	15.06	12.17
Current Portion of Long-Term Debt	-	-	-	-	2.59	7.02
Current Portion of Leases	1.56	1.64	1.3	1.21	1.15	0.94
Current Unearned Revenue	-	-	0.43	1	13.92	13.87
Other Current Liabilities	-	-	24.67	13.61	-	-
Total Current Liabilities	95.84	49.55	67.42	41.4	34.02	38.56
Long-Term Leases	0.42	1.93	3.58	-	1.32	-
Long-Term Unearned Revenue	-	-	-	-	18.41	11.15
Other Long-Term Liabilities	-	-	4.25	20.53	-	-
Total Liabilities	96.26	51.49	75.24	61.93	53.75	49.71

Shareholders' Equity

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Common Stock	0	0	0	0	0.01	0
Additional Paid-In Capital	1,166	774.57	433.22	404.06	398.73	345.41
Retained Earnings	-743.69	-611.26	-441.43	-418.5	-377.17	-334.7
Comprehensive Income & Other	-0.11	-	-	-	-	-
Total Common Equity	422.39	163.31	-8.21	-14.44	21.57	10.72
Shareholders' Equity	422.39	163.31	-8.21	-14.44	21.57	10.72
Total Liabilities & Equity	518.65	214.8	67.03	47.49	75.33	60.42

Additional Metrics

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Debt	1.98	3.58	4.88	1.21	5.06	7.96
Net Cash (Debt)	418.04	186.25	30.9	31.52	54.62	27.95
Net Cash Growth	238.65%	502.73%	-1.96%	-42.29%	95.42%	-27.48%
Net Cash Per Share	25.15	29.33	7.07	9.02	20.83	13.45
Filing Date Shares Outstanding	31.44	10.95	10.95	4.45	3.41	2.4
Total Common Shares Outstanding	29.34	10.95	4.53	3.62	3.39	2.24
Working Capital	346.98	161.18	-6.56	3.69	37.68	18.63
Book Value Per Share	14.40	14.92	-1.81	-3.98	6.36	4.78
Tangible Book Value	422.39	163.31	-8.21	-14.44	21.57	10.72
Tangible Book Value Per Share	14.40	14.92	-1.81	-3.98	6.36	4.78
Machinery	-	3.44	3.32	2.96	3.06	2.97
Leasehold Improvements	-	0.43	0.43	0.43	0.43	0.43

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error